Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. WEIGHT-LOSS MEDICATIONS MAY ... "This study allowed ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Eli Lilly’s weight loss drug Zepbound outperformed competitor Novo ... a 25% or more body weight reduction due to tirzepatide. By comparison, those who received semaglutide experienced a 16% ...

Weight-loss medications continue to grow in popularity ... Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week ...

A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...